Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Addy

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Obesity (Silver Spring, Md.)|August 23, 2007
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineNgozi Erondu, Carol Addy, Kaifeng Lu, et al.
Journal of Clinical Pharmacology|May 30, 2008
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteersCarol Addy, Paul Rothenberg, Susie Li, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Cell Metabolism|January 8, 2008
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intakeCarol Addy, Hamish Wright, Koen Van Laere, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Obesity (Silver Spring, Md.)|August 23, 2007
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineNgozi Erondu, Carol Addy, Kaifeng Lu, et al.
Journal of Clinical Pharmacology|May 30, 2008
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteersCarol Addy, Paul Rothenberg, Susie Li, et al.
Cell Metabolism|October 3, 2006
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu, Ira Gantz, Bret Musser, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Cell Metabolism|January 8, 2008
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intakeCarol Addy, Hamish Wright, Koen Van Laere, et al.
Pageof 3